Kirsten Skamstrup, Lene Heise Garvey, Carsten Bindslev-Jensen, Susanne Halken, Marianne Sjølin Frederiksen, Torsten Lauritsen, Thomas Houmann Petersen, Johannes Schmid, Sandra Viggers & Hans-Jørgen Malling,
Ugeskr Læger 2020;182:V07200537
In this review, we discuss anaphylaxis, which is a severe allergic condition with potentially life-threatening symptoms from airways or circulation and often associated with skin symptoms. First-line treatment is intramuscular adrenaline given by autoinjector for rapid administration. Initial dose for children < 25 kg is 0.15 mg and for children ≥ 25 kg and adults 0.3 mg. Repeated smaller doses of adrenaline is to be preferred. Patients with severe anaphylaxis will need an IV access for fluid replacement and supplementary oxygen. Antihistamines and steroids are only second-line treatment after adrenaline administration.